Skip to main content
Clinical Trials/NCT03949491
NCT03949491
Terminated
Not Applicable

Free Flap Breast Reconstruction Using Virtual Surgical Planning and 3-D Modeling

Case Comprehensive Cancer Center1 site in 1 country38 target enrollmentDecember 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Reconstruction
Sponsor
Case Comprehensive Cancer Center
Enrollment
38
Locations
1
Primary Endpoint
Mean operative time
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to determine if 3D modeling and Virtual Planning Surgery can improve the clinical outcome with patient who have a mastectomy requiring breast reconstruction.

Detailed Description

Primary objective: Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease dissection time and secondary perioperative complications including fat necrosis and donor site complications. Secondary objective: To propose incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes. This is a single-armed, prospective study to determine the feasibility of using 3-D virtual planning and medical modeling in breast cancer patients undergoing breast reconstruction

Registry
clinicaltrials.gov
Start Date
December 1, 2020
End Date
August 1, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects must have histologically or cytologically confirmed breast caner undergoing delayed or immediate breast reconstruction.
  • Performance statusECOG Performance status ≤ 2
  • Subjects must have normal organ and marrow function as defined below:
  • Hemoglobin ≥ 10.0 g/dl
  • Leukocytes ≥ 3,000/mcL
  • Absolute neutrophil count ≥ 1,500/mcL
  • Platelet count ≥ 100,000/mcL
  • Total bilirubin within normal institutional limits
  • AST (SGOT) ≤ 2.5 X institutional upper limit of normal
  • ALT (SGPT) ≤ 2.5 X institutional upper limit of normal

Exclusion Criteria

  • Subjects receiving any prior abdominoplasty or abdominal liposuction, or patient that plan on undergoing radiation therapy after reconstruction.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to IV contrast.
  • Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Pregnant or breastfeeding women are excluded from this study because IV contrast and CT scans have the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with breast cancer, breastfeeding should be discontinued.
  • Unsuitable donor site volume or vasculature based on pre-operative imaging or physical exam.

Outcomes

Primary Outcomes

Mean operative time

Time Frame: Up to 6 months after reconstruction

Mean operative time using 3D medical models of the abdomen to create a virtual plan to assist reconstruction.

Mean dissection time

Time Frame: Up to 6 months after reconstruction

Mean dissection time using 3D medical models of the abdomen to create a virtual plan to assist reconstruction.

Secondary Outcomes

  • Aesthetic outcomes as measured by the Harris scale(Up to 1 year after reconstruction)
  • Donor site complications(Up to 1 year after reconstruction)
  • Incidence of fat necrosis as measured by a grading system(1 week, 2 weeks, 6 weeks, 3 months, and 6 months post reconstruction.)
  • Patient satisfaction as measured by BREAST-Q scores(Up to 1 year after reconstruction)

Study Sites (1)

Loading locations...

Similar Trials